SCHEMBL6503433

SCHEMBL6503433

COC(=O)C(C)NC(=O)C1CCNCC1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PADI1 Q9ULC6 1/20 0.47
PADI4 Q9UM07 1/20 0.47
POLB P06746 2/20 0.42
ALDH1A1 P00352 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
CA14 Q9ULX7 1/20 0.40
GNAI3 P08754 1/20 0.40
GNAO1 P09471 1/20 0.40
GNAI1 P63096 1/20 0.40
TSHR P16473 3/20 0.39
GABRP O00591 1/20 0.39
GABRD O14764 1/20 0.39
GABRA1 P14867 1/20 0.39
GABRB1 P18505 1/20 0.39
GABRG2 P18507 1/20 0.39
GABRB3 P28472 1/20 0.39
GABRA5 P31644 1/20 0.39
GABRA3 P34903 1/20 0.39
GABRA2 P47869 1/20 0.39
GABRB2 P47870 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8296041 1.00 PADI1 (0.47) PADI1PADI4POLBALDH1A1SMN1; SMN2
SCHEMBL9961299 0.87 CA14 (0.47) PADI1PADI4POLBSMN1; SMN2CA14
SCHEMBL6495095 0.84 KMT2A (0.39) PADI1PADI4POLBALDH1A1SMN1; SMN2
SCHEMBL8297132 0.84 KMT2A (0.39) PADI1PADI4POLBALDH1A1SMN1; SMN2
SCHEMBL13033929 0.83 TSHR (0.47) PADI1PADI4POLBALDH1A1SMN1; SMN2
SCHEMBL29789574 0.83 TSHR (0.47) PADI1PADI4POLBALDH1A1SMN1; SMN2
SCHEMBL3919225 0.82 GABRP (0.47) PADI1PADI4POLBALDH1A1SMN1; SMN2
SCHEMBL13113457 0.82 GABRP (0.47) PADI1PADI4POLBALDH1A1SMN1; SMN2
SCHEMBL8311892 0.82 GABRP (0.47) PADI1PADI4POLBALDH1A1SMN1; SMN2
SCHEMBL13033925 0.80 PADI1 (0.54) PADI1PADI4POLBSMN1; SMN2TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2005016883-A2 ACRYLAMIDE DERIVATIVES AS VLA-1 INTEGRIN ANTAGONISTS AND USES THEREOF ICOS CORPORATION (US) 2005-02-24 WO disclosed